There is a gap between the world of clinical trials and the world of actual patients. In a randomised controlled trial, participants are carefully selected, rigorously monitored, and treated under conditions that bear only a passing resemblance to the messy, complicated reality of everyday clinical practice. Patients in the real world have comorbidities. They miss doses. They take other medications. They are older, younger, heavier, or sicker than the trial population that generated the evidence sitting in a drug’s regulatory dossier.
This gap has always existed. What has changed — dramatically, and relatively recently — is the pharmaceutical industry’s ability to close it. Real-world evidence (RWE) in pharmaceutical decision-making has moved from a supplementary data source to a central pillar of how drugs are developed, approved, priced, and monitored across the entire product lifecycle.
📊 The Scale of the Shift
The numbers tell the story more compellingly than any theoretical argument.
A 2025 analysis of regulatory submissions across major global markets found that RWE was included as supportive evidence in 67% of new drug applications reviewed by the EMA — up from 31% in 2019. The PMDA in Japan reported a similar trajectory, with RWE-supported submissions increasing by 89% between 2020 and 2025. The NMPA in China, following its 2020 guidance on real-world data, has seen RWE incorporated into over 140 regulatory decisions in the five years since publication.
The global real-world evidence market itself reflects this momentum. Valued at approximately USD 2.1 billion in 2023, it is projected to reach USD 5.8 billion by 2030 — a compound annual growth rate of 15.6%. That growth is not speculative. It is being driven by concrete regulatory policy shifts, payer demands for post-approval outcomes data, and the maturation of the health data infrastructure needed to generate credible RWE at scale.
🔍 What Real-World Evidence Actually Is
Real-world evidence is clinical evidence derived from the analysis of real-world data (RWD) — data collected outside the controlled environment of a traditional randomised clinical trial. The sources are varied and increasingly rich:
- Electronic health records (EHRs) — longitudinal patient data from hospital and clinic systems
- Claims and administrative databases — insurance and reimbursement records capturing prescribing patterns, procedures, and outcomes
- Patient registries — disease-specific databases tracking patient populations over time
- Wearables and digital health devices — continuous physiological data collected outside clinical settings
- Pharmacy dispensing records — real-world medication adherence and switching behaviour
The distinction between RWD and RWE is important and frequently blurred. RWD is the raw material — the data itself. RWE is the clinical evidence generated through the analysis of that data. The quality of RWE depends entirely on the rigour of the analytical methods applied to the underlying data, and this is where the field’s most significant methodological challenges reside.
🏥 Where RWE Is Changing Pharmaceutical Decision-Making
Regulatory Submissions and Label Extensions
The most visible application of real-world evidence in pharmaceutical decision-making is in regulatory submissions. RWE is increasingly used to support:
- Label extensions for approved products — demonstrating effectiveness in populations not included in the original trial
- Rare disease approvals — where randomised trial enrolment is impractical due to small patient populations
- Paediatric indications — where ethical constraints limit traditional trial designs
- Post-approval safety monitoring — fulfilling pharmacovigilance obligations with population-level outcomes data
A 2024 EMA review of RWE use in regulatory decisions identified 43 approved label extensions supported primarily by real-world data between 2021 and 2024 — a figure that would have been unthinkable a decade earlier. The PMDA’s 2023 guidance on the use of real-world data in regulatory submissions has similarly opened the door for RWE-supported applications in Japan across oncology, rare diseases, and chronic conditions.
Health Technology Assessment and Reimbursement
Perhaps the most commercially consequential application of RWE is in health technology assessment (HTA) and reimbursement decisions. Payers across European and Asian markets are increasingly unwilling to accept clinical trial efficacy data alone as the basis for pricing and reimbursement negotiations. They want to know what happens to real patients, in real clinical settings, over real timeframes.
The shift is structural. A 2025 survey of HTA bodies across twelve markets found that 78% now formally require or strongly encourage RWE submission as part of the reimbursement dossier for new medicines — up from 44% in 2020. For oncology products, that figure rises to 91%.
The commercial implications are significant. Products that can demonstrate real-world effectiveness aligned with — or exceeding — trial efficacy data command stronger reimbursement positions. Products where real-world outcomes diverge negatively from trial results face pricing pressure, restricted formulary access, or mandatory outcomes-based agreements.
A 2024 analysis of oncology reimbursement decisions across European markets found that products supported by robust RWE achieved average reimbursement rates 23% higher than comparable products relying solely on clinical trial data. The investment in generating credible real-world evidence is not academic — it is directly reflected in commercial outcomes.
Post-Market Safety Surveillance
Real-world evidence has fundamentally transformed pharmacovigilance. Traditional adverse event reporting systems — relying on voluntary spontaneous reports from healthcare professionals — capture an estimated less than 10% of actual adverse events occurring in clinical practice. RWE-based safety surveillance, drawing on EHR data and claims databases, provides a far more complete and timely picture of a product’s real-world safety profile.
The EMA’s EudraVigilance system and Japan’s MIHARI project both represent large-scale infrastructure investments in RWE-based pharmacovigilance. A 2025 analysis of signal detection timelines found that RWE-based surveillance systems identified safety signals an average of 7.3 months earlier than traditional spontaneous reporting systems — a difference with direct consequences for patient safety and regulatory response times.
⚠️ The Methodological Challenges That Cannot Be Ignored
Real-world evidence is not without its critics, and the criticism is not unfounded. The fundamental challenge of RWE is confounding — the reality that patients who receive a particular treatment in the real world are systematically different from those who do not, in ways that may influence outcomes independently of the treatment itself.
Randomised controlled trials eliminate confounding through randomisation. Real-world studies cannot randomise. They must instead rely on statistical methods — propensity score matching, instrumental variable analysis, difference-in-differences approaches — to approximate the causal inference that randomisation provides cleanly.
A 2024 methodological review of published RWE studies across oncology found that 41% had significant confounding risks that were either inadequately addressed or not acknowledged in the study conclusions. This is not a reason to dismiss RWE — it is a reason to demand methodological rigour in its generation and transparent reporting of its limitations.
Regulatory authorities are increasingly sophisticated in their evaluation of RWE quality. The EMA’s framework for RWE assessment explicitly evaluates data source quality, study design appropriateness, analytical method validity, and the plausibility of causal inference before accepting RWE as supportive evidence. Companies that submit RWE without adequate methodological justification are finding that regulators are well equipped to identify and challenge the weaknesses.
💡 Building a Credible RWE Strategy
For pharmaceutical companies navigating the growing importance of real-world evidence in pharmaceutical decision-making, the strategic imperatives are clear:
Start early. RWE generation cannot be an afterthought bolted onto a product’s lifecycle after approval. The most credible real-world evidence programmes are designed in parallel with the clinical development programme, with data collection infrastructure established before launch.
Choose data sources carefully. Not all real-world data is equal. The credibility of RWE depends on the completeness, accuracy, and representativeness of the underlying data source. A claims database that captures 30% of the relevant patient population generates weaker evidence than a registry capturing 85%.
Invest in methodological expertise. The analytical methods applied to real-world data are as important as the data itself. Epidemiologists, biostatisticians, and health economists with specific RWE expertise are not a luxury — they are a prerequisite for generating evidence that will withstand regulatory and HTA scrutiny.
Engage regulators proactively. Both the EMA and PMDA offer formal scientific advice processes that include RWE methodology. Companies that engage early, seek feedback on their RWE study designs, and incorporate regulatory input into their protocols generate evidence that is far more likely to be accepted and valued.
🏁 The Direction of Travel Is Clear
Real-world evidence in pharmaceutical decision-making is no longer an emerging trend. It is an established expectation — from regulators, from payers, and increasingly from prescribers and patients who want to know how a medicine performs in people like them, not just in the carefully selected participants of a pivotal trial.
The companies that build genuine RWE capabilities — investing in data infrastructure, methodological expertise, and proactive regulatory engagement — are positioning themselves for a competitive advantage that will compound over time. The companies that treat RWE as a compliance exercise, generating the minimum required to satisfy a reimbursement dossier, will find themselves increasingly disadvantaged in markets where the evidence bar continues to rise.
The gap between the clinical trial world and the real world has always existed. The question now is not whether to close it — but how quickly, and how credibly.
